CEO total compensation of $5,652,339 is within a reasonable range for a biotech CEO at a company with a roughly $380 million market cap, and the pay structure is appropriately weighted toward variable compensation — base salary of $864,010 represents only about 15% of total pay, with the remainder in performance bonuses and equity awards including performance stock awards tied to specific stock price hurdles. The prior year say-on-pay vote received 74% support (above the 70% threshold), and the company made visible changes in response to the prior year's lower 50.8% result by introducing performance stock awards aligned to stock price targets, which demonstrates responsive governance. The pay-for-performance alignment is acceptable: while the stock has declined sharply over the past year, the 3-year total return remains strongly positive and executive incentive pay is tied to meaningful performance conditions including stock price hurdles that require 56-100% price appreciation above the grant date price.

Non-audit fees (tax services of $147,924) represent approximately 8.3% of audit fees ($1,791,500), well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot be confirmed and therefore does not fire; no material restatements are disclosed; and Ernst & Young LLP is a Big 4 firm appropriate for a company of Akebia's size and complexity.